PULM Key Statistics, Chart & Performance
The current stock price of PULM is 2.3 USD. In the past month the price decreased by -42.64%. In the past year, price decreased by -61.73%.
PULM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.39 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 19.99 | 499.91B | ||
| MRK | MERCK & CO. INC. | 12.33 | 269.55B | ||
| PFE | PFIZER INC | 7.9 | 143.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.65 | 115.47B | ||
| ZTS | ZOETIS INC | 19.82 | 55.38B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 10.07 | 23.89B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.79 | 11.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.60B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.73B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.06B |
Related stock screener links
About PULM
Company Profile
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Company Info
PULMATRIX INC
945 Concord Street, Suite 1217
Framingham MASSACHUSETTS 02421 US
CEO: Teofilo Raad
Employees: 2
Phone: 18883554440
PULMATRIX INC / PULM FAQ
Can you describe the business of PULMATRIX INC?
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Can you provide the latest stock price for PULMATRIX INC?
The current stock price of PULM is 2.3 USD.
Does PULMATRIX INC pay dividends?
PULM does not pay a dividend.
What is the ChartMill rating of PULMATRIX INC stock?
PULM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of PULMATRIX INC (PULM)?
PULMATRIX INC (PULM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).
Should I buy PULM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PULM.
How many employees does PULMATRIX INC have?
PULMATRIX INC (PULM) currently has 2 employees.
PULM Technical Analysis
PULM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PULM. No worries on liquidiy or solvency for PULM as it has an excellent financial health rating, but there are worries on the profitability.
PULM Financial Highlights
Over the last trailing twelve months PULM reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS increased by 35.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.85% | ||
| ROE | -131.42% | ||
| Debt/Equity | 0 |
PULM Forecast & Estimates
For the next year, analysts expect an EPS growth of -10% and a revenue growth 1% for PULM